<DOC>
	<DOCNO>NCT01148160</DOCNO>
	<brief_summary>Multiple factor associate large variability voriconazole exposure follow standard dose administration , non-linear saturable pharmacokinetics , drug-drug interaction , liver disease , patient age , genetic polymorphism metabolic enzyme . Voriconazole extensively metabolize human hepatic enzyme , primarily mediate CYP2C19 . The polymorphisms account relatively large portion inter-individual variance observe voriconazole plasma concentration . However , limited data relationship voriconazole blood level clinical outcome safety Asian population . The purpose study investigate relationship voriconazole blood level genetic polymorphism , safety , clinical outcome immunocompromised patient invasive pulmonary aspergillosis .</brief_summary>
	<brief_title>Voriconazole Trough Plasma Levels : Genetic Polymorphism , Efficacy , Safety Patients With Hematologic Malignancy</brief_title>
	<detailed_description>The investigator try establish routine clinical practice voriconazole therapeutic drug monitoring improve efficacy safety outcome . In Korean patient hematologic malignancy , investigator also want propose optimal dose guideline voriconazole different genetic polymorphism .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>item male female â‰¥ 15 year age immunocompromised patient hematologic disorder patient receive voriconazole due treat proven , probable invasive ( pulmonary ) aspergillosis severe hepatic dysfunction ( t.bil , AST , ALT , ALP &gt; 5 x upper normal limit ) experience hypersensitivity azoles pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>voriconazole</keyword>
	<keyword>invasive pulmonary aspergillosis</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>therapeutic drug monitoring</keyword>
	<keyword>genetic polymorphism</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>